Oric Pharmaceuticals
ORIC
113 hedge funds and large institutions have $478M invested in Oric Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 18 reducing their positions, and 20 closing their positions.
206% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 18
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
5.42% more ownership
Funds ownership: 94.92% → 100.34% (+5.4%)
1% more funds holding
Funds holding: 112 → 113 (+1)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
46% less capital invested
Capital invested by funds: $879M → $478M (-$401M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.8M |
| 2 |
Millennium Management
New York
|
+$5.24M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.84M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$3.76M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.22M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.38M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$2.52M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.31M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.24M |
ORIC Hedge Fund Activity: Q2 2024 in Review
113 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q2 2024, worth a combined $478M — down 46% from $879M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ORIC positions and 20 closed out — a net gain of 2 holders — while 55 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $14.8M. The largest seller was Invesco, cutting an estimated $4.22M.
- 113 institutional investors held Oric Pharmaceuticals (ORIC) as of Q2 2024, up from 112 in Q1 2024.
- Funds reported $478M of Oric Pharmaceuticals stock for Q2 2024, down 46% quarter-over-quarter.
- 22 funds opened new Oric Pharmaceuticals positions in Q2 2024 and 20 closed out, a net change of +2 holders.
- The largest Oric Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $14.8M added.
- The largest Oric Pharmaceuticals seller in Q2 2024 was Invesco, an estimated $4.22M sold.
Based on aggregated 13F filings for Q2 2024.